Canagliflozin heMihydrate
|
|
- CAS-Nr.
- 928672-86-0
- Englisch Name:
- Canagliflozin heMihydrate
- Synonyma:
- Canagliflozin hydrate;Cagliflozin heMihydrate;(2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol Hemihydrate;Cageline;NSC 36678;NSC 406879;Kagliflozin;TA7284 hemihydrate;TA-7284 hemihydrate;Invokana hemihydrate
- CBNumber:
- CB32677171
- Summenformel:
- 2(C24H25FO5S).H2O
- Molgewicht:
- 462.53
- MOL-Datei:
- 928672-86-0.mol
|
Canagliflozin heMihydrate Eigenschaften
- Schmelzpunkt:
- 94-96°C
- storage temp.
- Hygroscopic, Refrigerator, under inert atmosphere
- Löslichkeit
- DMSO (Slightly), Methanol (Slightly)
- Aggregatzustand
- Solid
- Farbe
- White to Off-White
- Stabilität:
- Hygroscopic
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
Bildanzeige (GHS) |
|
Alarmwort |
Warnung |
Gefahrenhinweise |
Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
H302 |
Gesundheitsschädlich bei Verschlucken. |
Akute Toxizität oral |
Kategorie 4 |
Warnung |
src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizität (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
src="/GHS07.jpg" width="20" height="20" /> |
|
|
Sicherheit |
P261 |
Einatmen von Staub vermeiden. |
P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen. |
|
Canagliflozin heMihydrate Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Canagliflozin, an orally active and selective sodium–glucose
cotransporter 2 (SGLT2) inhibitor, was co-developed by
Mitsubishi Tanabe Pharma and Johnson & Johnson (J&J) for the
treatment of type 2 diabetes mellitus (T2DM) and obesity. The
drug was approved in March by the U.S. FDA and launched in
April 2013 in the U.S. SGLT2 is involved in the glucose re-absorption
pathway in the kidney, and its inhibition increases urinary
glucose excretion, and reduces plasma glucose and HbA1c levels.
In addition, canagliflozin is safe in combination with other commonly
used antidiabetic agents and has a significant effect on body
weight reduction. A recently published process patent from
ScinoPharm Taiwan describes the synthesis of canagliflozin.
Verwenden
Canagliflozin Hemihydrate is a derivative of Canagliflozin (C175190), which is a sodium/glucose cotransporter 2 (SGLT2) inhibitor. Canagliflozin has been shown to dose dependently reduce calculated renal threshold for glucose excretion and increase urinary glucose excretion. Canagliflozin is a candidate for the treatment of type 2 diabetes and obesity.
Synthese
Synthesis of the aglycone region of canagliflozin was described
in a separate patent by first condensing commercially available 5-
bromo-2-methylbenzoyl chloride (14) and 2-(4-fluorophenyl)-
thiophene (15) under Friedel¨CCrafts acylation conditions to give
ketone 16 in 69% yield as a crystalline solid. Ketone 16 was then
reduced with triethylsilyl hydride in the presence of BF3Et2O at
low temperature to give aglycone bromide 17 in 70% yield. The
precursor for the glycoside moiety, commercially available glycoside
triol 18, was selectively treated with t-butyldiphenylsilyl
chloride (TBDPSCl) in THF in the presence of imidazole to give
the bis-silyl ether 19 in 81% yield. Next, a unique, stereospecific
b-C-arylglucosidation was developed to secure the union of the
aglyone- and glycoside-containing portions of canagliflozin.
Bromide 17 was subjected to magnesium powder under standard
Grignard conditions prior to treatment with AlCl3 in THF in situ.
This resulting mixture was then exposed to a solution of compound
19 in PhOMe which had been pre-treated with n-BuLi, and the entire mixture was then warmed to 150 ?? for 5 h to ultimately
give the b-anomer 20 in 56% yield. Finally, removal of the silyl
groups within 20 with tetrabutyl ammonium fluoride (TBAF) in
THF delivered canagliflozin hydrate (III) in 73% yield.
![Synthesis_928672-86-0](https://www.chemicalbook.com/NewsImg/2021-02-09/20210209240008881457848537.jpg)
Canagliflozin heMihydrate Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Canagliflozin heMihydrate Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 271)Lieferanten
- Canagliflozin hydrate (2:1)
- Canagliflozin heMihydrate
- D-Glucitol, 1,5-anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]Methyl]-4-Methylphenyl]-, hydrate (2:1)
- Canagliflozin heMihydrates
- (1S)-1,5-Anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol hydrate (2:1)
- Cageline
- Invokana hemihydrate
- JNJ 28431754 hemihydrate
- JNJ28431754 hemihydrate
- JNJ-28431754 hemihydrate
- JNJ28431754 HEMIHYDRATE; JNJ-28431754 HEMIHYDRATE; JNJ 28431754 HEMIHYDRATE; TA-7284 HEMIHYDRATE; TA7284 HEMIHYDRATE; INVOKANA HEMIHYDRATE
- TA7284 hemihydrate
- TA-7284 hemihydrate
- bis((2S,3R,4R,5S,6R)-2-(3-{[5-(4-fluorophenyl)thio phen-2-yl]methyl}-4-methylphenyl)-6-(hydroxymet hyl)oxane-3,4,5-triol) hydrate
- Canagliflozin (API)
- Canagli ozin Hemi hydrate
- (1S)-1,5-anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol Hemihydrate
- Canagliflozin hemihydrate (JNJ 28431754)
- TIANFU-CHEM 928672-86-0 Canagliflozin heMihydrate
- NSC 36678
- NSC 406879
- Cagliflozin heMihydrate
- (2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol Hemihydrate
- Canagliflozin hydrate
- Kaglie net semihydrate
- (2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol hydrate
- Kagliflozin
- 928672-86-0
- 2C24H25FO5SH2O
- C24H25FO5SH2O
- C24H25FO5S12H2O
- Canagliflozin
- API
- 928672-86-0